NCT06541249View on ClinicalTrials.gov

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
Polycythemia Vera (PV)Essential Thrombocythemia (ET)Myelofibrosis (MF)
Interventions
DRUG

Methotrexate (MTX)

MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.

Trial Locations (1)

10029

RECRUITING

Ruttenberg Treatment Center, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER